AbbVie (ABBV) Gains from Sales and Divestitures (2013 - 2016)

AbbVie (ABBV) has 4 years of Gains from Sales and Divestitures data on file, last reported at $6.1 million in Q2 2016.

• Quarterly Gains from Sales and Divestitures rose 11.16% year-over-year to $6.1 million in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $6.1 million (up 11.16% YoY) and the FY2015 annual result came in at $5.7 million, down 14.1% from the prior year.
• Gains from Sales and Divestitures improved to $6.1 million in Q2 2016 per ABBV's latest filing, from $5.5 million in the prior quarter.
• Across five years, Gains from Sales and Divestitures topped out at $7.6 million in Q4 2013 and bottomed at $5.3 million in Q1 2015.
• The 4-year median for Gains from Sales and Divestitures is $6.3 million (2014), against an average of $6.4 million.
• The widest annual swing landed in 2015, when Gains from Sales and Divestitures decreased 14.53%; it then increased 11.16% in 2016.
• Tracing ABBV's Gains from Sales and Divestitures over 4 years: stood at $7.6 million in 2013, then fell by 12.11% to $6.6 million in 2014, then fell by 14.1% to $5.7 million in 2015, then rose by 7.65% to $6.1 million in 2016.
• Per Business Quant, the three latest ABBV Gains from Sales and Divestitures figures stand at $6.1 million (Q2 2016), $5.5 million (Q1 2016), and $5.7 million (Q4 2015).

Peer Comparison